Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation

Figure 2 Metabolic dysfunction-associated fatty liver disease models, pathological alterations, and specific concentrations. A: Gross specimen of a liver; B: Liver Hematoxylin & eosin staining (100 ×); C: Oil red O staining (100 ×); D: Liver carnitine palmitoyl transferase-II specific concentration (ng/mg protein); E: Liver CD44 levels; F: Liver CD24 levels; G: Liver alpha-fetoprotein levels. ^aP < 0.05, ^bP < 0.01, compared with the normal control group; NC: Normal control; HCC: Hepatocellular carcinoma; MAFL: Metabolic dysfunction-associated fatty liver; MASH: Metabolic dysfunction-associated steato-hepatitis; LC: Liver cirrhosis; CPT-II: Carnitine palmitoyl transferase-II; AFP: Alpha-fetoprotein; H&E: Hematoxylin & eosin.